Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297884433> ?p ?o ?g. }
- W4297884433 abstract "Abstract Pleomorphic xanthoastrocytoma (PXA) is a rare subset of primary pediatric glioma with 70% 5-year disease free survival. However, up to 20% of cases present with local recurrence and malignant transformation into more aggressive type anaplastic PXA (AXPA) or glioblastoma. The understanding of disease etiology and mechanisms driving PXA and APXA are limited, and there is no standard of care. Therefore, development of relevant preclinical models to investigate molecular underpinnings of disease and to guide novel therapeutic approaches are of interest. Here, for the first time we established, and characterized a patient-derived xenograft (PDX) from a leptomeningeal spread of a patient with recurrent APXA bearing a novel CDC42SE2-BRAF fusion. An integrated -omics analysis was conducted to assess model fidelity of the genomic, transcriptomic, and proteomic/phosphoproteomic landscapes. A stable xenoline was derived directly from the patient recurrent tumor and maintained in 2D and 3D culture systems. Conserved histology features between the PDX and matched APXA specimen were maintained through serial passages. Whole exome sequencing (WES) demonstrated a high degree of conservation in the genomic landscape between PDX and matched human tumor, including small variants (Pearson’s r = 0.794–0.839) and tumor mutational burden (~ 3 mutations/MB). Large chromosomal variations including chromosomal gains and losses were preserved in PDX. Notably, chromosomal gain in chromosomes 4–9, 17 and 18 and loss in the short arm of chromosome 9 associated with homozygous 9p21.3 deletion involving CDKN2A/B locus were identified in both patient tumor and PDX sample. Moreover, chromosomal rearrangement involving 7q34 fusion; CDC42SE-BRAF t (5;7) (q31.1, q34) (5:130,721,239, 7:140,482,820) was identified in the PDX tumor, xenoline and matched human tumor. Transcriptomic profile of the patient’s tumor was retained in PDX (Pearson r = 0.88) and in xenoline (Pearson r = 0.63) as well as preservation of enriched signaling pathways (FDR Adjusted P < 0.05) including MAPK, EGFR and PI3K/AKT pathways. The multi-omics data of (WES, transcriptome, and reverse phase protein array (RPPA) was integrated to deduce potential actionable pathways for treatment (FDR < 0.05) including KEGG01521, KEGG05202, and KEGG05200. Both xenoline and PDX were resistant to the MEK inhibitors trametinib or mirdametinib at clinically relevant doses, recapitulating the patient’s resistance to such treatment in the clinic. This set of APXA models will serve as a preclinical resource for developing novel therapeutic regimens for rare anaplastic PXAs and pediatric high-grade gliomas bearing BRAF fusions." @default.
- W4297884433 created "2022-10-01" @default.
- W4297884433 creator A5000532556 @default.
- W4297884433 creator A5006404776 @default.
- W4297884433 creator A5013091468 @default.
- W4297884433 creator A5021599737 @default.
- W4297884433 creator A5023762376 @default.
- W4297884433 creator A5026115229 @default.
- W4297884433 creator A5027787903 @default.
- W4297884433 creator A5028535795 @default.
- W4297884433 creator A5031825011 @default.
- W4297884433 creator A5039277834 @default.
- W4297884433 creator A5047963496 @default.
- W4297884433 creator A5050941851 @default.
- W4297884433 creator A5052581052 @default.
- W4297884433 creator A5059076044 @default.
- W4297884433 creator A5065902063 @default.
- W4297884433 creator A5070502683 @default.
- W4297884433 creator A5073818711 @default.
- W4297884433 creator A5079043556 @default.
- W4297884433 creator A5081964920 @default.
- W4297884433 creator A5086463369 @default.
- W4297884433 creator A5089196334 @default.
- W4297884433 creator A5089265440 @default.
- W4297884433 date "2022-09-20" @default.
- W4297884433 modified "2023-09-27" @default.
- W4297884433 title "Establishment and characterization of patient-derived xenograft from leptomeningeal spread of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion" @default.
- W4297884433 cites W1918248652 @default.
- W4297884433 cites W1962284334 @default.
- W4297884433 cites W1975444221 @default.
- W4297884433 cites W1983340023 @default.
- W4297884433 cites W1988017366 @default.
- W4297884433 cites W2004946118 @default.
- W4297884433 cites W2010498181 @default.
- W4297884433 cites W2010760434 @default.
- W4297884433 cites W2015660037 @default.
- W4297884433 cites W2020328382 @default.
- W4297884433 cites W2021341670 @default.
- W4297884433 cites W2023447695 @default.
- W4297884433 cites W2045587177 @default.
- W4297884433 cites W2075754351 @default.
- W4297884433 cites W2090120422 @default.
- W4297884433 cites W2093903659 @default.
- W4297884433 cites W2102170491 @default.
- W4297884433 cites W2110128697 @default.
- W4297884433 cites W2118952409 @default.
- W4297884433 cites W2120061253 @default.
- W4297884433 cites W2122004774 @default.
- W4297884433 cites W2122481654 @default.
- W4297884433 cites W2131976264 @default.
- W4297884433 cites W2141149378 @default.
- W4297884433 cites W2141355900 @default.
- W4297884433 cites W2146772089 @default.
- W4297884433 cites W2147199538 @default.
- W4297884433 cites W2148789757 @default.
- W4297884433 cites W2157771579 @default.
- W4297884433 cites W2172099875 @default.
- W4297884433 cites W2188398652 @default.
- W4297884433 cites W2293035635 @default.
- W4297884433 cites W2343384188 @default.
- W4297884433 cites W2366536035 @default.
- W4297884433 cites W2408915103 @default.
- W4297884433 cites W2513017614 @default.
- W4297884433 cites W2561818048 @default.
- W4297884433 cites W2587703250 @default.
- W4297884433 cites W2751238974 @default.
- W4297884433 cites W2768207518 @default.
- W4297884433 cites W2804385878 @default.
- W4297884433 cites W2806423392 @default.
- W4297884433 cites W2886102891 @default.
- W4297884433 cites W2894448865 @default.
- W4297884433 cites W2900044275 @default.
- W4297884433 cites W2902206407 @default.
- W4297884433 cites W2923435363 @default.
- W4297884433 cites W2942352570 @default.
- W4297884433 cites W2949584167 @default.
- W4297884433 cites W2973617143 @default.
- W4297884433 cites W2976477572 @default.
- W4297884433 cites W2990567654 @default.
- W4297884433 cites W2991604482 @default.
- W4297884433 cites W3027245190 @default.
- W4297884433 cites W3030381575 @default.
- W4297884433 cites W3096828292 @default.
- W4297884433 cites W3112887863 @default.
- W4297884433 cites W3123814388 @default.
- W4297884433 cites W3212059340 @default.
- W4297884433 cites W4205696707 @default.
- W4297884433 cites W4251184610 @default.
- W4297884433 doi "https://doi.org/10.21203/rs.3.rs-2026518/v1" @default.
- W4297884433 hasPublicationYear "2022" @default.
- W4297884433 type Work @default.
- W4297884433 citedByCount "0" @default.
- W4297884433 crossrefType "posted-content" @default.
- W4297884433 hasAuthorship W4297884433A5000532556 @default.
- W4297884433 hasAuthorship W4297884433A5006404776 @default.
- W4297884433 hasAuthorship W4297884433A5013091468 @default.
- W4297884433 hasAuthorship W4297884433A5021599737 @default.
- W4297884433 hasAuthorship W4297884433A5023762376 @default.
- W4297884433 hasAuthorship W4297884433A5026115229 @default.
- W4297884433 hasAuthorship W4297884433A5027787903 @default.